LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...
Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.
Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback